<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801138</url>
  </required_header>
  <id_info>
    <org_study_id>08-647</org_study_id>
    <nct_id>NCT00801138</nct_id>
  </id_info>
  <brief_title>The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine</brief_title>
  <official_title>The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that adding dexamethasone significantly prolongs the
      duration of ropivacaine and bupivacaine analgesia, and that the magnitude of the effect
      differs among the two local anaesthetics.. Participants will be patients undergoing shoulder
      surgery with an interscalene nerve block.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blinded randomized study of four groups of patients undergoing shoulder
      surgery using interscalene nerve blocks. Participants will be randomized into one of four
      groups:

        -  Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline (placebo) for interscalene
           block;

        -  Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline (placebo);

        -  Ropivacaine and steroid: 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed
           with the local anesthetic;

        -  Bupivacaine and steroid: 30 ml 0.5% bupivacaine plus dexamethasone 8 mg (2 ml) mixed
           with the local anesthetic.

      The primary outcome is the duration of the interscalene nerve block which is time to first
      analgesic request after PACU discharge.

      Kaplan-Meier survival density estimation and stratified Cox proportional hazard regression
      were used to compare groups.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A strong primary outcome crosses the efficacy boundary at the interim analysis
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Duration of the Interscalene Nerve Block Which is Time to First Administration of Pain Medication After Block</measure>
    <time_frame>Postoperative day 1, 2 and 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Report of Pain</measure>
    <time_frame>Postoperative day 1, 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Maximum VAS Pain Scores at Rest</measure>
    <time_frame>Postoperative day 1, 2 and 3</time_frame>
    <description>Visual Analogue Scale (VAS) pain scale is used to describe the severity or intensity of pain. It ranges from 0 to 10. Zero indicates&quot;no pain at all&quot; and ten indicates &quot;worst pain imaginable.&quot; , The higher of the score, the worse of the pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Three-day Opioid Consumption in Oral Oxycodone Equivalent</measure>
    <time_frame>Postoperative day 1, 2 and 3</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Anesthesia, Local</condition>
  <condition>Shoulder Surgery</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3 Ropivacaine and dexamethasone: 30 ml 0.5% ropivacaine mixed with dexamethasone 8 mg (2 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 4 Bupivacaine and steroid: 30 ml 0.5% bupivacaine mixed with dexamethasone 8 mg (2 ml).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>2 ml 0.9% saline (placebo)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>dexamethasone 8 mg (2 ml)</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine</intervention_name>
    <description>30 ml 0.5% ropivacaine</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>30 ml 0.5% bupivacaine</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 75 years

          -  Patients undergoing shoulder procedures, such as rotator cuff repair, capsular shift,
             shoulder arthroplasty, subacromial decompression

        Exclusion Criteria:

          -  Contraindications to interscalene block (Coagulopathy, infection at the needle
             insertion site, moderate to severe chronic obstructive pulmonary disease,
             contralateral pneumothorax or diaphragmatic paralysis)

          -  Pregnancy

          -  Pre-existing neuropathy involving the surgical limb

          -  Systemic glucocorticoid treatment (for 2 weeks or more) within six months of surgery

          -  Chronic opioid use (greater than 30 mg oral oxycodone equivalent per day)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Cummings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel I Sessler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ivan Parra Sanchez, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <results_first_submitted>July 18, 2016</results_first_submitted>
  <results_first_submitted_qc>March 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2017</results_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ropivacaine</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>glucocorticoid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
Ropivacaine
Placebo: saline</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
Bupivacaine
Placebo: saline</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Group 3 Ropivacaine and dexamethasone:
Ropivacaine plus dexamethasone
Ropivacaine
Dexamethasone: steroid</description>
        </group>
        <group group_id="P4">
          <title>Group 4</title>
          <description>Group 4 Bupivacaine and steroid:
Bupivacaine plus dexamethasone
Bupivacaine
Dexamethasone: steroid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
Ropivacaine
Placebo: saline</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
Bupivacaine
Placebo: saline</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Group 3 Ropivacaine and dexamethasone:
Ropivacaine plus dexamethasone
Ropivacaine
Dexamethasone: steroid</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>Group 4 Bupivacaine and steroid:
Bupivacaine plus dexamethasone
Bupivacaine
Dexamethasone: steroid</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="54"/>
            <count group_id="B4" value="54"/>
            <count group_id="B5" value="218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="44" upper_limit="65"/>
                    <measurement group_id="B2" value="60" lower_limit="51" upper_limit="68"/>
                    <measurement group_id="B3" value="59" lower_limit="49" upper_limit="68"/>
                    <measurement group_id="B4" value="58" lower_limit="53" upper_limit="64"/>
                    <measurement group_id="B5" value="58" lower_limit="50" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Duration of the Interscalene Nerve Block Which is Time to First Administration of Pain Medication After Block</title>
        <time_frame>Postoperative day 1, 2 and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
Ropivacaine
Placebo: saline</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
Bupivacaine
Placebo: saline</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 Ropivacaine and dexamethasone:
Ropivacaine plus dexamethasone
Ropivacaine
Dexamethasone: steroid</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 Bupivacaine and steroid:
Bupivacaine plus dexamethasone
Bupivacaine
Dexamethasone: steroid</description>
          </group>
        </group_list>
        <measure>
          <title>The Duration of the Interscalene Nerve Block Which is Time to First Administration of Pain Medication After Block</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="9.7" upper_limit="13.8"/>
                    <measurement group_id="O2" value="14.8" lower_limit="11.8" upper_limit="18.1"/>
                    <measurement group_id="O3" value="22.2" lower_limit="18.0" upper_limit="28.6"/>
                    <measurement group_id="O4" value="22.4" lower_limit="20.5" upper_limit="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Report of Pain</title>
        <time_frame>Postoperative day 1, 2 and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
Ropivacaine
Placebo: saline</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
Bupivacaine
Placebo: saline</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 Ropivacaine and dexamethasone:
Ropivacaine plus dexamethasone
Ropivacaine
Dexamethasone: steroid</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 Bupivacaine and steroid:
Bupivacaine plus dexamethasone
Bupivacaine
Dexamethasone: steroid</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Report of Pain</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="9.2" upper_limit="13.8"/>
                    <measurement group_id="O2" value="14.7" lower_limit="13.4" upper_limit="17.9"/>
                    <measurement group_id="O3" value="22.3" lower_limit="18.0" upper_limit="27.2"/>
                    <measurement group_id="O4" value="25.7" lower_limit="21.7" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Maximum VAS Pain Scores at Rest</title>
        <description>Visual Analogue Scale (VAS) pain scale is used to describe the severity or intensity of pain. It ranges from 0 to 10. Zero indicates“no pain at all” and ten indicates “worst pain imaginable.” , The higher of the score, the worse of the pain.</description>
        <time_frame>Postoperative day 1, 2 and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
Ropivacaine
Placebo: saline</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
Bupivacaine
Placebo: saline</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 Ropivacaine and dexamethasone:
Ropivacaine plus dexamethasone
Ropivacaine
Dexamethasone: steroid</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 Bupivacaine and steroid:
Bupivacaine plus dexamethasone
Bupivacaine
Dexamethasone: steroid</description>
          </group>
        </group_list>
        <measure>
          <title>Median Maximum VAS Pain Scores at Rest</title>
          <description>Visual Analogue Scale (VAS) pain scale is used to describe the severity or intensity of pain. It ranges from 0 to 10. Zero indicates“no pain at all” and ten indicates “worst pain imaginable.” , The higher of the score, the worse of the pain.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="O3" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O4" value="3" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Three-day Opioid Consumption in Oral Oxycodone Equivalent</title>
        <time_frame>Postoperative day 1, 2 and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
Ropivacaine
Placebo: saline</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
Bupivacaine
Placebo: saline</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Group 3 Ropivacaine and dexamethasone:
Ropivacaine plus dexamethasone
Ropivacaine
Dexamethasone: steroid</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Group 4 Bupivacaine and steroid:
Bupivacaine plus dexamethasone
Bupivacaine
Dexamethasone: steroid</description>
          </group>
        </group_list>
        <measure>
          <title>Total Three-day Opioid Consumption in Oral Oxycodone Equivalent</title>
          <units>milligrams</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="45" upper_limit="153"/>
                    <measurement group_id="O2" value="85" lower_limit="51" upper_limit="118"/>
                    <measurement group_id="O3" value="79" lower_limit="45" upper_limit="153"/>
                    <measurement group_id="O4" value="60" lower_limit="47" upper_limit="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days after surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
Ropivacaine
Placebo: saline</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
Bupivacaine
Placebo: saline</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>Group 3 Ropivacaine and dexamethasone:
Ropivacaine plus dexamethasone
Ropivacaine
Dexamethasone: steroid</description>
        </group>
        <group group_id="E4">
          <title>Group 4</title>
          <description>Group 4 Bupivacaine and steroid:
Bupivacaine plus dexamethasone
Bupivacaine
Dexamethasone: steroid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel I Sessler, MD</name_or_title>
      <organization>Cleveland Clinic Foundation</organization>
      <phone>2164458396</phone>
      <email>sesslerd@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

